Immunovant Inc [IMVT] stock is trading at $30.02, up 1.42%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMVT shares have gain 2.91% over the last week, with a monthly amount glided 4.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Oppenheimer reaffirmed its Outperform rating on October 09, 2024, and elevated its price target to $53. On March 28, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $50 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $50 on March 13, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $51 as its price target on February 20, 2024. Wolfe Research started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $55. In a note dated December 12, 2023, Deutsche Bank initiated an Buy rating and provided a target price of $50 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $24.67 and $45.58 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $30.02 at the most recent close of the market. An investor can expect a potential return of 42.67% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -189.93%, Pretax Profit Margin comes in at -181.26%, and Net Profit Margin reading is -181.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.52 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.58 points at the first support level, and at 29.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.27, and for the 2nd resistance point, it is at 30.51.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 13.08. Further, the Quick Ratio stands at 13.08, while the Cash Ratio is 12.44.
Transactions by insiders
Recent insider trading involved Salzmann Peter, Chief Executive Officer, that happened on Oct 16 ’24 when 9095.0 shares were sold. Chief Medical Officer, Macias William L. completed a deal on Oct 16 ’24 to sell 3188.0 shares. Meanwhile, Chief Legal Officer Levine Mark S. sold 2860.0 shares on Oct 16 ’24.
